Vincent S, Maire P H, Bataillard T, Denjean E, Ducrozet P, Laffont A, Visent C, Jelliffe R W
ADCAPT, Hôpital A.-Charial, Hospices Civils de Lyon 1, Francheville, France.
Pathol Biol (Paris). 1996 Sep;44(7):667-74.
In previous works, we have shown: i) good parameter predictive performances of the USC*PACK Clinical Programs for amikacin therapy in the elderly, ii) no significant difference generally detected between estimated parameter values at days 7 and 14 after the beginning of therapy, iii) assurance of neither accumulation nor toxicity during therapy up to 14 days or more, in our conditions. The objectives of this study were to explore which elements best explained differences found in the pharmacokinetic parameters (PK) of the elderly patients, who had received several courses of amikacin therapy.
patients' pharmacokinetic data and their medical records were retrospectively analyzed. Only patients who received amikacin therapy with at least a 2-month washout between their courses were studied. Two parameterizations of the 1-compartment PK model were used: one without covariates: Kel-Vol, where Kel = elimination rate constant and Vol = distribution volume, and another including covariates: Ks-Vs, with: Kel = Ks. CCr + Ki, where: Ks = renal fraction of Kel, Ki - non renal elimination, CCr = estimated creatinine clearance, and Vs = Vol/W, where Vs = distribution volume per kg and W = weight.
14 patients, 3 men and 11 women, fulfilled the criteria (4 of them satisfied the condition with 3 courses). They were 66 to 89 years old, their mean weight was 53.86 +/- 11.03 kg (46-71.5), their CCr averaged: 55.45 +/- 17.16 mL/min (14.84-96.27).
Among patients exhibiting changes (67%) in PK parameters between different courses of therapy, 42% could have the variability related to covariate (W, CCr) changes; in the others 58% the residual variability could be explained by different factors: severity of infection, immune system deficiency and/or particularly parenteral nutrition. Based on these result, we suggest including septic choc and parenteral nutrition as covariates during amikacin adaptive control.
在之前的研究中,我们已经表明:i)USC*PACK临床程序对老年患者阿米卡星治疗的参数预测性能良好;ii)治疗开始后第7天和第14天的估计参数值之间通常未检测到显著差异;iii)在我们的条件下,治疗长达14天或更长时间内既无蓄积也无毒性。本研究的目的是探讨哪些因素能最好地解释接受多疗程阿米卡星治疗的老年患者药代动力学参数(PK)中发现的差异。
对患者的药代动力学数据及其病历进行回顾性分析。仅研究那些在疗程之间有至少2个月洗脱期的接受阿米卡星治疗的患者。使用了单室PK模型的两种参数化方法:一种无协变量:Kel-Vol,其中Kel =消除速率常数,Vol =分布容积;另一种包括协变量:Ks-Vs,其中:Kel = Ks·CCr + Ki,其中:Ks = Kel的肾清除分数,Ki =非肾清除,CCr =估计的肌酐清除率,且Vs = Vol/W,其中Vs =每千克分布容积,W =体重。
14例患者,3例男性和11例女性,符合标准(其中4例满足3个疗程条件)。他们年龄在66至89岁之间,平均体重为53.86±11.03 kg(46 - 71.5),平均CCr为:55.45±17.16 mL/min(14.84 - 96.27)。
在不同疗程治疗之间PK参数出现变化的患者中(67%),42%的变异性可能与协变量(W、CCr)变化有关;在其他58%的患者中,残余变异性可能由不同因素解释:感染严重程度、免疫系统缺陷和/或特别是肠外营养。基于这些结果,我们建议在阿米卡星适应性控制期间将脓毒症休克和肠外营养作为协变量纳入。